New clinical study shows promising survival rates for patients with glioblastomas while reducing burden on health resources

Based on recent information on the mechanisms of chemotherapy, a team of researchers of the McGill University Health Centre developed a new clinical approach to increase the efficiency of treatment in glioblastomas that increased the median survival to 22 months – bringing much needed hope to those affected by this aggressive disease. With their new approach, the team of researchers added chemotherapy prior to radiotherapy, also called neo-adjuvant chemotherapy. Giving neo-adjuvant chemotherapy prevented the tumour from progressing during recovery and increased the patients’ survival.
McGill University Health Centre